

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) ~~Use of a~~ A method for increasing the number of islets of Langerhans cells, treatment of prediabetes, treatment or prevention of insulin-dependent diabetes, prevention of non-insulin-dependent diabetes, or treatment of early non-insulin-dependent diabetes, comprising administering to a patient in need thereof an effective amount of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for increasing the number of islets of Langerhans cells.

2. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor~~ A method according to Claim 1, wherein in increasing the number of islets of Langerhans cells, the patient is in need of in the context of the treatment and/or or prevention of diabetes, its complications and/or its or a complication thereof or a related pathologies pathology thereof.

3. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the treatment of prediabetes.

4. (Currently Amended) ~~Use~~ A method according to Claim 3, ~~for which the~~ wherein said prediabetes is an insulin-dependent prediabetes.

5. (Currently Amended) ~~Use~~ A method according to Claim 3, ~~for which the~~ wherein said prediabetes is a non-insulin-dependent prediabetes.

6. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the~~ A method according to claim 1, which is for the treatment and/or or prevention of insulin-dependent diabetes.

7. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the prevention of non-insulin-dependent diabetes.

8. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament~~ A method according to claim 1, which is for the treatment of early non-insulin-dependent diabetes.

9. (Currently Amended) ~~Use~~ A method according to claim 3, ~~for which the said treatment or prevention is by increasing~~ wherein the number of islets of Langerhans cells are increased.

10. (Currently Amended) ~~Use of a kynurenine 3-hydroxylase inhibitor in combination with one or more immunosuppressants, for the manufacture of a medicament~~ A method according to claim 1, which is for the prevention ~~and/or~~ or treatment of insulin-dependent diabetes, further comprising administering an immunosuppressant.

11. (Currently Amended) ~~Use~~ A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has an impairment in the number of islets of Langerhans cells.

12. (Currently Amended) ~~Use~~ A method according to Claim 11, ~~for which the~~ wherein said patient shows a decrease in the number of islets of Langerhans cells of at least 40%.

13. (Currently Amended) ~~Use~~ A method according to Claim 11, ~~for which the~~ wherein said patient shows a decrease in the number of islets of Langerhans cells of ~~between 50% and to~~ to 90%.

14. (Currently Amended) ~~Use~~ A method according to claim 1, ~~wherein the~~ which is suitable for the said treatment and/or the said prevention in the case of a patient ~~with~~ has glucose intolerance.

15. (Currently Amended) ~~Use~~ A method according to Claim 14, ~~for which the~~ wherein said patient presents a fasting glycaemia of ~~between 1.10 g/l and to~~ to 1.26 g/l and a glycaemia after meals a meal of ~~between 1.40 g/l and to~~ to 2 g/l ~~after meals~~.

16. (Currently Amended) ~~Use~~ A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has one or more anti-islets of Langerhans cells immunological markers.

17. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) indicate(s) the existence of an autoimmune response of the body directed against the antigenic markers of the body's islets of Langerhans cells.

18. (Currently Amended) Use A method according to Claim 16, ~~for which the~~ wherein said marker(s) is (are) ~~chosen from the~~ anti-islet (ICA), anti-glutamic acid decarboxylase (GAD), anti-tyrosine phosphatase (IA-2) ~~and~~ or anti-(pro)insulin (AIA) auto-antibodies, or the anti-carboxypeptidase H, anti-64kD ~~and~~ or anti-heat shock protein antibodies.

19. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient ~~with~~ has insulin resistance.

20. (Currently Amended) Use A method according to Claim 19, ~~for which the~~ wherein said patient responds partially or not at all to insulin secreted by the beta cells or injected.

21. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a level of glycated haemoglobin of higher than 7%.

22. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient has islets of Langerhans cells showing an anomaly of insulin secretion in response to glucose.

23. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient presents a suppression of the early peak of insulin secretion.

24. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said patient shows related hyperglycaemia and obesity.

25. (Currently Amended) Use A method according to Claim 24, ~~for which the~~ wherein said patient suffers from paediatric obesity.

26. (Currently Amended) Use A method according to claim 1, ~~which is suitable for the said treatment and/or the said prevention in the case of a~~ wherein the patient presenting any has a diabetic risk factor.


27. (Currently Amended) Use A method according to Claim 25, ~~for which the~~ wherein said risk factor is ~~chosen from~~ familial history, gestational diabetes, excess weight, obesity, insufficient physical exercise, high blood pressure, a high level of triglycerides, hyperlipidaemia and or inflammation.

28. (Currently Amended) Use A method according to claim 1, comprising the in vitro treatment of isolated islets of Langerhans cells with ~~the~~ said kynurenine 3-hydroxylase inhibitor.

29. (Currently Amended) ~~Process~~ A process for increasing the number or the insulin-secreting capacity of islets of Langerhans cells, comprising the in vitro application of a kynurenine 3-hydroxylase inhibitor to ~~the~~ said cells.


30-32. (Cancelled)


33. (Currently Amended) Use A method according to claim 1, ~~for which the~~ wherein said kynurenine 3-hydroxylase inhibitor is a compound of ~~the general~~ formula (I) or (II):



in which:

- W represents a divalent radical ~~chosen from the following radicals:~~





• R<sup>1</sup> represents a ~~radical chosen from~~ linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and~~ or an optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, a heterocyclic radical, an aryl radical ~~and~~ or a heteroaryl radical;

• R<sup>2</sup> is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxycarbonyl, aryl, heteroaryl, cycloalkyl ~~and~~ or a heterocyclic radical;

• R<sup>3</sup> is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, cycloalkyl ~~and~~ or a heterocyclic radical;

• R<sup>2</sup> and R<sup>3</sup> together ~~also possibly forming a group~~ optionally form =CR<sup>16</sup>R<sup>17</sup>; or alternatively together ~~forming~~ form, with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

• R<sup>4</sup> is ~~chosen from~~ hydroxyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, -N(R<sup>12</sup>R<sup>12'</sup>), -N(R<sup>12</sup>)OR<sup>13</sup>, linear or branched alkyl containing ~~from~~ 1 to 14 carbon atoms ~~and~~ or an optionally substituted, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl ~~and~~ or a heterocyclic radical;

• R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup>, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, ~~and~~ or a nitro, cyano, hydroxyl, trifluoromethyl, alkyl, alkoxy, cycloalkyl or aryl radical;

• the radicals R<sup>5</sup> and R<sup>6</sup>, ~~on the one hand~~, or R<sup>6</sup> and R<sup>7</sup>, ~~on the other hand~~, may also form, together with the carbon atoms to which they are attached, a benzene ring optionally substituted by one or more groups, which may be identical or different, ~~chosen from~~ and are a halogen atom, a trifluoromethyl, cyano or nitro radical, an alkyl radical ~~and~~ or an alkoxy radical;

• R<sup>9</sup> represents hydrogen or an alkyl radical;

• R<sup>10</sup> is ~~chosen from~~ an alkyl, an aryl ~~and~~ or a heteroaryl radical;

• R<sup>12</sup> and R<sup>12'</sup>, which may be identical or different, are ~~chosen~~, independently of each other, ~~from~~ hydrogen ~~and~~ or an alkyl, alkenyl, alkynyl, alkylcarbonyl, aryl or heteroaryl radical; or alternatively R<sup>12</sup> and R<sup>12'</sup> may form, together with the nitrogen atom to which they are attached, a monocyclic or bicyclic heterocyclic group containing a total of 5 to 10 atoms, among which 1, 2, 3 or 4 are ~~chosen~~, independently of each other, ~~from~~ nitrogen, oxygen ~~and~~ or sulfur,

the said heterocyclic radical also optionally comprising 1, 2, 3 or 4 double bonds and optionally being substituted by one or more ~~chemical~~ groups, which may be identical or different, ~~chosen from~~ and are hydroxyl, halogen atom, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclic radical ~~and or~~ trifluoromethyl;

- $R^{13}$  is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, alkenyl, alkynyl, aryl, heteroaryl, -N( $R^{12}R^{12'}$ ) or -N( $R^{12}$ )OR $^{13}$  radical;

- $R^{14}$  is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylcarbonyl, alkoxycarbonyl, aryl, arylalkyl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- $R^{14}$  may also form a bond with  $R^2$ , thus forming a double bond between the carbon atoms respectively bearing the substituents  $R^{14}$  and  $R^2$ ; or alternatively  $R^{14}$  forms, with  $R^2$  and with the carbon atoms that bear them, a ring containing a total of 3, 4, 5, 6 or 7 carbon atoms, among which 1, 2 or 3 may be replaced with an atom ~~chosen from~~ nitrogen, oxygen ~~and or~~ sulfur, the said ring possibly optionally comprising one or more unsaturations in the form of (a) double bond(s), and being optionally substituted by one or more radicals, which may be identical or different, ~~chosen from~~ and are oxo, alkoxy, alkoxycarbonyl ~~and or~~ alkylcarbonyloxy;

- $R^{15}$  is ~~chosen from~~ hydrogen, a halogen atom, hydroxyl, thiol, carboxyl, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkoxycarbonyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocyclyloxy, alkylthio, alkenylthio, alkynylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclylthio, aryl, heteroaryl, cycloalkyl ~~and or~~ a heterocyclic radical;

- $R^{14}$  and  $R^{15}$  ~~also possibly forming~~ optionally form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical;

- $R^{16}$  and  $R^{17}$ , which may be identical or different, ~~are chosen~~, independently of each other, ~~from~~ hydrogen, a halogen atom, an alkyl, aryl, heteroaryl or cycloalkyl radical ~~and or~~ a heterocyclic radical; or alternatively

- $R^{16}$  and  $R^{17}$  form, together with the carbon atom that bears them, a cycloalkyl radical or a heterocyclic radical; and

- $R^{11}$  is ~~chosen from~~ hydrogen ~~and or~~ an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl radical, ~~and any~~ or a protecting group for an amine function;

~~and also the possible~~ or a geometrical ~~and/or or~~ optical ~~isomers~~ isomer thereof, ~~and possi-~~

ble ~~or a tautomeric forms~~ form thereof;

~~the solvates and hydrates of these compounds; or a solvate or hydrate thereof; or a~~  
~~and also the possible salts~~ salt thereof with a pharmaceutically acceptable acid or base, or  
~~alternatively the a pharmaceutically acceptable prodrugs of these compounds~~ prodrug thereof.

34-54. (Cancelled)

55. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase.

56. (New) A method according to claim 33, wherein the compound administered is capable of the inhibition of kynurenine 3-hydroxylase in an *in vitro* test.